Should I buy Charles River Laboratories (CRL) stock or is it too late?
⭐ The most reliable of them, either direction: Deutsche Bank — 72% of its targets hit on this sector (292 calls tested). It aims for $320 (+7.0 %), call made on September 26, 2026, maturing on September 26, 2027 (18 d ago).
Firm-by-firm track record on Charles River Laboratories
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Citigroup | 78 % | +43.0 % | 9 | $265 -11% |
| Morgan Stanley | 67 % | +37.6 % | 9 | $340 +14% |
| Jefferies | 87 % | +33.0 % | 15 | $340 +14% |
| Evercore ISI Group | 67 % | +30.9 % | 6 | $330 +10% |
| JP Morgan | 38 % | +7.0 % | 8 | $310 +4% |
| Baird | 50 % | +3.5 % | 10 | $334 +12% |
| UBS | 29 % | -5.3 % | 7 | $175 -41% |
| SunTrust Robinson Humphrey | 100 % | +86.4 % | 6 | — |
✅ Reasons to believe
- 82% of analysts rate it a buy (Buy consensus, 11 ratings) — a sign of market conviction.
- Median price target $324, i.e. +8% from the current price ($299).
- The most reliable firm on CRL, Jefferies (87% hit rate, 15 scored calls), targets $340 (call made on September 28, 2026, maturing on September 28, 2027) (+14%) in its most recent call.
- 6 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 11 ratings, 2 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on CRL
Median target $324 (+8%) · 11 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Charles River Laboratories now?
We won't decide for you. The facts: 82% of analysts rate it a buy, median target $324 (+8%), and Jefferies (most reliable on CRL, 87%) targets $340. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Charles River Laboratories?
Not according to analysts: the median target ($324) is still +8% above the current price ($299) (most reliable on CRL: Jefferies, 87%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Charles River Laboratories still worth investing in?
It depends on the gap between the price ($299) and its estimated value: analysts target $324 on median (+8%), with 82% buys (most reliable on CRL: Jefferies, 87%). Cross-check with their real reliability on CRL and the cautions above. Information, not advice.
What's the main risk in buying CRL?
The consensus is not unanimous: of 11 ratings, 2 are neutral.
→ Go deeper: the full Charles River Laboratories profile (consensus, analyst reliability, price target, performance).